Iron overload and chelation therapy in myelodysplastic syndromes

Slides:

Advertisements

Similar presentations

Efficacy and Safety of Deferasirox (Exjade®) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from.

Advertisements

Perimenopausal migraine in women with vasomotor symptoms E. Anne MacGregor Maturitas Volume 71, Issue 1, Pages (January 2012) DOI: /j.maturitas

The Survival Kit: Software to analyze survival data including possibly correlated random effects G. Mészáros, J. Sölkner, V. Ducrocq Computer Methods and.

Garlic decreases liver and kidney receptor for advanced glycation end products expression in experimental diabetes Khaled K. Al-Qattan, Mohamed H. Mansour,

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature María Teresa Martínez, José Alejandro Pérez-Fidalgo, Paloma Martín-Martorell,

Metastatic melanoma treatment: Combining old and new therapies Ryan J. Davey, Andre van der Westhuizen, Nikola A. Bowden Critical Reviews in Oncology /

Eribulin—A review of preclinical and clinical studies

Gastric cancer Critical Reviews in Oncology / Hematology

Umesh K. Narta, Shamsher S. Kanwar, Wamik Azmi

Exercise issues in older cancer survivors

Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review Cloé Brami, Ting Bao, Gary Deng Critical.

Poor glycemic control and decreased renal function are associated with increased intrarenal RAS activity in Type 2 diabetes mellitus S. Nakatani, E.

Volume 27, Issue 2, Pages (April 2008)

Novel targets in gastric and esophageal cancer

Critical Reviews in Oncology / Hematology

Nicoletta Colombo, Martin Gore

Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control Daniel M. Mueller, Martina Allenspach,

Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias Acta.

Invasive lobular breast cancer and its variants: How special are they for systemic therapy decisions? Séverine Guiu, Anita Wolfer, William Jacot, Pierre.

Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes J. Loeffler-Ragg, U. Germing, W.R. Sperr, H. Herrmann, H. Zwierzina,

Organization of the clinical activity of Geriatric Oncology: Report of a SIOG (International Society of Geriatric Oncology) task force Silvio Monfardini,

A Proton Pump Inhibitor a Day Keeps the Iron Away

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis Peyman Hadji Critical Reviews in Oncology.

Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis

The case for wider use of recombinant factor VIII concentrates

A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer Sandro Pignata, Enrico.

P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency

Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature Omar Abdel-Rahman,

Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey Lazzaro Repetto Critical.

The see-saw of Keap1-Nrf2 pathway in cancer

Amy M. Lin, Charles J. Ryan, Eric J. Small

Jonathan P. Evans, Paul A. Sutton, Boleslaw K. Winiarski, Stephen W

Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review.

Understanding coronary artery disease patients’ decisions regarding the use of chelation therapy for coronary artery disease: Descriptive decision modeling

A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC) Giorgio Arcangeli,

Abhimanyu Ghose, Ria Kundu, Tahir Latif

Critical Reviews in Oncology / Hematology

Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment Judith Maresch, Sebastian F. Schoppmann,

P. Therasse, S. Carbonnelle, J. Bogaerts

Martin Dreyling, MD, PhD Seminars in Hematology

Olfa Baroudi, Amel Benammar-elgaaied

Clinically useful prognostic factors in acute myeloid leukemia

Long non-coding RNA CASC2 in human cancer

Gwo Yaw Ho, Natasha Woodward, Jermaine I.G. Coward

Critical Reviews in Oncology / Hematology

Primary renal carcinoid: Treatment and prognosis

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario Alfredo Addeo, Fabrizio Tabbò, Tim Robinson, Lucio Buffoni, Silvia Novello Critical.

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer Miguel.

Gerhard J. Molderings Critical Reviews in Oncology / Hematology

Ascites and Hepatorenal Syndrome: Pathophysiology and Management

How I treat thalassemia

Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and.

H. Clark Hoagland, M.D. Mayo Clinic Proceedings

Epidemiology of Myelodysplastic Syndromes

Oxidative stress in autism

Gene therapy in haematology and oncology

Hemochromatosis Protein (HFE) Knockout Mice As a Novel Model of Hemochromatosis: Implications for Study and Management of Iron-Overload Cardiomyopathy

Mechanisms of iron hepatotoxicity

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Serum cholinesterase activity in the diagnosis of nonalcoholic fatty liver disease in type 2 diabetic patients O.O. Ogunkeye, E.K. Chuhwak, A.A.E. Otokwula

A Proton Pump Inhibitor a Day Keeps the Iron Away

Joseph W. Eschbach, John W. Adamson Kidney International

Paul C. Adams, James C. Barton Journal of Hepatology

Antibiotic De-Escalation

Ayman O. Soubani, MD, John C. Ruckdeschel, MD

Increasing incidence of brain tumours in sparsely populated areas

Age and cerebral circulation

Volume 14, Issue 1, Pages (May 2007)

Volume 10, Issue 3, Pages (September 2006)

Managing the Complications of Cirrhosis

Presentation transcript:

Iron overload and chelation therapy in myelodysplastic syndromes Sally Temraz, Valeria Santini, Khaled Musallam, Ali Taher Critical Reviews in Oncology / Hematology Volume 91, Issue 1, Pages 64-73 (July 2014) DOI: 10.1016/j.critrevonc.2014.01.006 Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

Fig. 1 Mechanism of action of iron chelators in the management of iron overload. TBI: transferrin bound iron; ROS: reactive oxygen species; NTBI: non-transferrin bound iron; TFR-1: transferrin receptor-1; LPI: labile plasma iron; DMT1: divalent metal transporter 1. Critical Reviews in Oncology / Hematology 2014 91, 64-73DOI: (10.1016/j.critrevonc.2014.01.006) Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

Fig. 2 Suggested algorithm for the use of iron chelators in MDS patients. *Contraindications to deferasirox include: creatinine clearance<40ml/min or serum creatinine more than twice the upper limit of normal, platelet counts <50×109/L, severe hepatic impairment (Child–Pugh class C) and hypersensitivity to deferasirox. *Contraindications to deferoxamine include: severe renal failure or anuria, Clcr<10ml/min and hypersensitivity to deferoxamine. Critical Reviews in Oncology / Hematology 2014 91, 64-73DOI: (10.1016/j.critrevonc.2014.01.006) Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions